Apealea® (Paclical®) has been assessed from clinical trials and has been approved in ovarian cancer in Russia, Kazakhstan and within the EU1. Elevar, our partner, is responsible for submission to US Food and Drug Administration, FDA, for approval also in the US. Regarding docetaxel micellar, Oasmia has partnered with The Swiss Group for Clinical Research, SAKK, to conduct the first clinical Phase 1B trial of the compound in advanced prostate cancer.
1Indication and product name may differ between regions.
|Product||Indication||Pre-clinical||Phase I||Phase II||Phase III||Registration/ approval||Commercial Launch||Geography|
|Apealea®/ Paclical® (paclitaxel)||Ovarian cancer||EU/EEA|
|Docetaxel micellar||Prostate cancer||EU/EEA|